Supplements

Fish Oil and Brain Health: What a Two-Year DHA Trial Actually Found

The omega-3 reached the brain. The benefit did not follow. What that gap means for anyone taking fish oil for their memory.

Medically Reviewed By: Rhonda Collins, FNP-C | September 15, 2026 | 6 min read

Share

Copy link

The fish oil bottle on the counter is easy to stop noticing. Taking it can become part of the day, especially when the reason is simple: protect the brain and memory. Then a 2026 clinical trial put that idea through an unusually direct test: Fish oil reached their brains. Memory did not move. High-dose DHA reached the participants’ central nervous systems, but it did not improve cognition or preserve brain structure over two years in the older adults studied. [1]

That is the bottom line, but not a verdict that fish oil is useless. It is a sharper lesson. A supplement can change a biological measurement without changing the health outcome a person wants. This trial showed that difference unusually clearly.

What did the 2026 DHA trial actually test?

The PreventE4 trial was a phase IIa, randomized, double-blind, placebo-controlled study conducted at the University of Southern California. It enrolled 365 adults ages 55 to 80 who did not have dementia, consumed less than 200 milligrams of DHA per day, and had at least one cardiovascular or dementia risk factor. Participants received either 2,000 milligrams of DHA or placebo daily for 24 months. Nearly half, 47%, carried an APOE4 variant associated with higher Alzheimer’s disease risk. [1]

The trial’s main question was biochemical, not whether DHA prevented dementia. At six months, the researchers measured the change in the ratio of DHA to arachidonic acid in cerebrospinal fluid, the fluid surrounding the brain and spinal cord. Cognitive tests and MRI measurements of hippocampal volume, cortical thickness, and other brain structures were secondary or exploratory outcomes over 24 months. [1]

This hierarchy matters. The study was designed first to establish whether a high DHA dose could reach its central nervous system target. It was not a definitive Alzheimer’s prevention trial.

The DHA arrived, but memory did not move

The DHA group had a clear biochemical response. Cerebrospinal-fluid DHA rose by about 17%, and the red-blood-cell omega-3 index rose from 4.9% to 11.0%. The study’s prespecified primary measurement was different: the cerebrospinal-fluid DHA-to-arachidonic-acid ratio changed by +0.17 in the DHA group and -0.02 in the placebo group at six months. The 17% increase and the +0.17 ratio change are not two ways of stating the same number. [1]

Despite that target engagement, the researchers found no treatment difference in cognitive performance or brain volumes over 24 months. The DHA group did not show less hippocampal shrinkage than the placebo group. In plain language, the supplement was absorbed and DHA reached the central nervous system, but the clinical benefit people hope to buy for memory did not follow during this trial. [1]

That disconnect rules out one convenient explanation for earlier negative trials in this population: that DHA simply failed to reach the brain. It does not prove that every omega-3 supplement, dose, duration, or use will have the same result.

What the null result does and does not mean

The supported conclusion is narrow: 2,000 milligrams of DHA daily did not improve the measured cognitive or structural outcomes over 24 months in cognitively unimpaired older adults with low DHA intake and at least one dementia risk factor. The trial does not settle separate questions about cardiovascular indications, pregnancy, treatment of deficiency, prescription omega-3 therapy, or people with different health profiles. [1,2]

The study also has limits. It took place at one center. Participants were relatively young and highly educated, with preserved cognition, little hippocampal shrinkage, and cognitive scores that improved in both groups. Those features left limited decline for a treatment to slow. The 38% dropout rate, largely associated with COVID-19, reduced statistical power and may have introduced bias because people who withdrew differed from those who completed the trial. [1]

APOE4 was not ignored. Participants were stratified by APOE4 status, and the paper reported genotype-stratified analyses. DHA delivery did not meaningfully differ between carriers and non-carriers. The reported subgroup analyses also did not establish cognitive or structural benefit for either group. A subgroup result from this trial should not be used to promise memory protection based on someone’s APOE4 status. [1]

Could whole diet matter more than one capsule?

The researchers proposed that a single nutrient may be too narrow for a process shaped by several pathways. Vascular and metabolic risk, inflammation, physical activity, and the way the brain transports and metabolizes DHA may all influence cognitive aging. They argued that future work should focus on brain DHA metabolism, more sensitive measures, and multimodal strategies rather than simply escalating the supplement dose. [1]

In Keck Medicine’s account of the study, lead researcher Hussein Yassine also suggested that omega-3s may work better as part of a Mediterranean-style diet than as an isolated supplement. That is a hypothesis, not something this trial tested or proved. [3]

This distinction protects against replacing one oversimplified claim with another. The trial does not show that a particular diet prevents Alzheimer’s disease. It shows that changing one biochemical target with DHA alone did not change the measured brain outcomes in this population and timeframe.

What can an omega-3 blood test tell you?

An omega-3 blood test can answer a status question. Individual fatty acids can be measured in blood, and red-blood-cell measurements reflect longer-term intake better than a plasma or serum value that can vary with a recent meal. In this trial, the red-blood-cell omega-3 index confirmed that the DHA group’s systemic omega-3 status changed. [1,2]

Mito’s Omega-3 and Omega-6 Fatty Acid Profile measures fatty acids including EPA, DHA, DPA w3, an EPA+DPA+DHA composite, and the omega-6/omega-3 ratio. Those measurements can show your status and, when tests are compared thoughtfully, whether intake or supplementation was followed by a change.

They cannot diagnose cognitive decline, predict who will develop dementia, or prove that a higher omega-3 result protects memory. Even the meaning of the omega-6/omega-3 ratio has limits: experts have not established one optimal ratio, and the ratio can hide the levels of individual fatty acids. [2] For more context, see what the omega-6 to omega-3 ratio can and cannot show.

What should you do if you take fish oil for your brain?

Do not stop a clinician-directed supplement because of one news story. Fish oil and prescription omega-3 products can be used for reasons this cognition trial did not study. Review the reason, formulation, and dose with the clinician who recommended it, especially if you take medicines that affect blood clotting. [2,4]

If you take fish oil daily on your own, ask two separate questions. Was your omega-3 status low to begin with, and did it change after supplementation? A blood test can help answer those. Is the supplement protecting your memory? This trial says that moving DHA into the blood and central nervous system did not establish that benefit over two years in the population studied. A higher number is evidence of exposure and response, not a receipt for memory protection.

This article is for informational purposes only and does not provide medical advice, diagnosis, or treatment. It is not a substitute for care tailored to your health history, medications, and goals.

Resources

1. Yassine HN, et al. CNS target engagement of high-dose DHA supplementation in older adults at risk for dementia: a randomised, double-blind, placebo-controlled trial. eBioMedicine. 2026.

2. National Institutes of Health Office of Dietary Supplements. Omega-3 Fatty Acids: Fact Sheet for Health Professionals.

3. Keck Medicine of USC. Fish oil supplements may not prevent Alzheimer’s-related decline.

4. National Center for Complementary and Integrative Health. Omega-3 Supplements: What You Need To Know.